The Efficacy of Lumateperone in Patients With Bipolar Depression With Mixed Features
The Journal of Clinical Psychiatry · 2023
DOI: 10.4088/jcp.22m14739 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Psychiatry, 2023. Verfasst von Roger S McIntyre und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Bipolar Disorder, Major Depressive Disorder, Antipsychotic Agents. Die Arbeit wurde bisher 19-mal zitiert (Crossref).
Themen: Depression
Abstract (Originalsprache)
Objective
A post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled outpatient study investigated efficacy of lumateperone 42 mg in patients with bipolar I or bipolar II disorder and experiencing a major depressive episode (MDE) stratified by the presence of mixed features.
Methods
Adults (18-75 years) with bipolar I or bipolar II disorder experiencing an MDE, defined by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, criteria, were randomized 1:1 to 6-week oral lumateperone 42 mg/d or placebo (conducted November 2017-March 2019). Montgomery-Asberg Depression Rating Scale (MADRS) total score, Clinical Global Impression Scale-Bipolar Version-Severity (CGI-BP-S) total score, and Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) were analyzed in patients (N = 376) categorized as having mixed features (Young Mania Rating Scale [YMRS] score ≥ 4 and ≤ 12, 41.5%) or not having mixed features (YMRS < 4, 58.5%) at baseline. Treatment-emergent adverse events (TEAEs) including mania/hypomania were assessed.
Results
At day 43, lumateperone significantly improved MADRS and CGI-BP-S total scores change from baseline compared with placebo for patients with mixed features (MADRS least squares mean difference [LSMD] = -4.4, P < .01; CGI-BP-S LSMD = -0.7, P < .05) and without mixed features (MADRS LSMD = -4.2, P < .001, CGI-BP-S LSMD = -1.0, P < .001). Q-LES-Q-SF percent score significantly improved at day 43 with lumateperone vs placebo in patients with mixed features (LSMD = 5.9, P < .05), with numerical improvements in patients without mixed features (LSMD = 2.6, P = .27). TEAEs of mania/hypomania were rare.
Conclusions
Lumateperone 42 mg significantly improved symptoms of depression and disease severity in patients with an MDE associated with bipolar I or bipolar II disorder, with or without mixed features. Trial Registration: ClinicalTrials.gov identifier: NCT03249376.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
- Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada.
- Corresponding author: Roger S. McIntyre, MD, Brain and Cognition Discovery Foundation, 77 Bloor St, West Suite 600, Toronto, ON M5S 1M2, Canada (roger.mcintyre@bcdf.org).
- Intra-Cellular Therapies, Inc., New York, New York.
- Department of Psychiatry, University of California, San Diego, La Jolla, California.
Zitieren
APA
McIntyre, R. S., Durgam, S., Huo, J., Kozauer, S. G., & Stahl, S. M. (2023). The Efficacy of Lumateperone in Patients With Bipolar Depression With Mixed Features. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.22m14739
Vancouver
McIntyre RS, Durgam S, Huo J, Kozauer SG, Stahl SM. The Efficacy of Lumateperone in Patients With Bipolar Depression With Mixed Features. The Journal of Clinical Psychiatry. 2023. doi:10.4088/jcp.22m14739
BibTeX
@article{McIntyre2023,
author = {McIntyre, Roger S and Durgam, Suresh and Huo, Jason and Kozauer, Susan G and Stahl, Stephen M},
title = {The Efficacy of Lumateperone in Patients With Bipolar Depression With Mixed Features},
journal = {The Journal of Clinical Psychiatry},
year = {2023},
doi = {10.4088/jcp.22m14739}
}
EUVIMED